{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:37:55Z","timestamp":1786991875908,"version":"build-2736575974"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["3R21AI149321-01S1"],"award-info":[{"award-number":["3R21AI149321-01S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R01AI148446-01A1"],"award-info":[{"award-number":["1R01AI148446-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jconrel.2023.10.025","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T11:45:47Z","timestamp":1697888747000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation"],"prefix":"10.1016","volume":"364","author":[{"given":"Peng","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Sodhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pekosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongpeng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.10.025_bb0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin-angiotensin system in cardiovascular disease","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2165\/00002512-199405050-00007","article-title":"Changes in the renin-angiotensin-aldosterone axis in later life","volume":"5","author":"Belmin","year":"1994","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0015","first-page":"677","article-title":"Renin-angiotensin-aldosterone system (RAAS) and its pharmacologic modulation","volume":"23","author":"Giestas","year":"2010","journal-title":"Acta Medica Port."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0020","first-page":"P27","article-title":"Activated renin-angiotensin-aldosterone system and its effects on cardiovascular system during 20-days horizontal bed rest","volume":"2","author":"Haruna","year":"1995","journal-title":"J. Gravit. Physiol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0025","doi-asserted-by":"crossref","first-page":"e00917","DOI":"10.1002\/prp2.917","article-title":"The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: key agents for treatment","volume":"10","author":"Lumbers","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0030","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","author":"Remuzzi","year":"2005","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0035","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/01.WNL.0000130360.21618.D0","article-title":"Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke","volume":"63","author":"Sokol","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0040","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1172\/JCI117757","article-title":"A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction","volume":"95","author":"Stevens","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258684","article-title":"Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease","volume":"16","author":"Cremer","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105924","article-title":"Renin angiotensin aldosterone system in pulmonary fibrosis: pathogenesis to therapeutic possibilities","volume":"174","author":"Gupta","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10753-020-01337-3","article-title":"Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications","volume":"44","author":"Iwasaki","year":"2021","journal-title":"Inflammation"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/thx.2006.061945","article-title":"Role of the renin-angiotensin system in ventilator-induced lung injury: an in vivo study in a rat model","volume":"62","author":"Jerng","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12272-020-01301-7","article-title":"Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective","volume":"44","author":"Lee","year":"2021","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.667254","article-title":"The role of renin-angiotensin-aldosterone system in the heart and lung: focus on COVID-19","volume":"12","author":"Mascolo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0075","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.4049\/jimmunol.1900579","article-title":"A dynamic variation of pulmonary ACE2 is required to modulate neutrophilic inflammation in response to Pseudomonas aeruginosa lung infection in mice","volume":"203","author":"Sodhi","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0080","doi-asserted-by":"crossref","first-page":"ofab170","DOI":"10.1093\/ofid\/ofab170","article-title":"Renin angiotensin aldosterone system antagonism in 2019 novel coronavirus acute lung injury","volume":"8","author":"Ventura","year":"2021","journal-title":"Open Forum. Infect. Dis."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.025_bb0085","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4049\/jimmunol.2200533","article-title":"An innate checkpoint determines immune dysregulation and immunopathology during pulmonary murine coronavirus infection","volume":"210","author":"Grabherr","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-023-07980-z","article-title":"Predictive markers related to local and systemic inflammation in severe COVID-19-associated ARDS: a prospective single-center analysis","volume":"23","author":"Lieberum","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0095","doi-asserted-by":"crossref","unstructured":"C.D. Russell, N.I. Lone, J.K. Baillie. Comorbidities, multimorbidity and COVID-19. Nat. Med. (2023); 29(2): 334-343.","DOI":"10.1038\/s41591-022-02156-9"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2022.23257","article-title":"Long-term (180-Day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial","volume":"329","author":"R.-C.A.P.I. Writing Committee for the","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00424-012-1120-0","article-title":"ACE2, angiotensin-(1-7), and mas: the other side of the coin","volume":"465","author":"Bader","year":"2013","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/MNH.0b013e3282f945c2","article-title":"New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy","volume":"17","author":"Batlle","year":"2008","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0115","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1007\/s00018-004-4241-6","article-title":"Physiological roles of angiotensin-converting enzyme 2","volume":"61","author":"Danilczyk","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0120","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/SHK.0000000000000633","article-title":"Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease","volume":"46","author":"Jia","year":"2016","journal-title":"Shock"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1050-1738(02)00233-5","article-title":"The role of ACE2 in cardiovascular physiology","volume":"13","author":"Oudit","year":"2003","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0135","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1165\/rcmb.2020-0322PS","article-title":"Targeting ACE2 for COVID-19 therapy: opportunities and challenges","volume":"64","author":"Jia","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0140","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0145","doi-asserted-by":"crossref","first-page":"H980","DOI":"10.1152\/ajpheart.00476.2005","article-title":"Regulation of ACE2 and ANG-(1-7) in the aorta: new insights into the renin-angiotensin system in the control of vascular function","volume":"289","author":"Dantas","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1152\/physiolgenomics.00312.2005","article-title":"ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR","volume":"27","author":"Diez-Freire","year":"2006","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FJC.0b013e3180986219","article-title":"ACE2: a new target for cardiovascular disease therapeutics","volume":"50","author":"Raizada","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0160","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1042\/CS20110668","article-title":"Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes","volume":"123","author":"Tikellis","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41581-022-00642-4","article-title":"Therapeutic advances in COVID-19","volume":"19","author":"Murakami","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0170","doi-asserted-by":"crossref","unstructured":"C.F. Anderson, Q. Wang, D. Stern, E.K. Leonard, B. Sun, K.J. Fergie, C.-y. Choi, J.B. Spangler, J. Villano, A. Pekosz, C.F. Brayton, H. Jia, H. Cui, Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention, Matter, 6 (2023) 583\u2013604.","DOI":"10.1016\/j.matt.2022.11.027"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1042\/CS20120162","article-title":"Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions","volume":"123","author":"Burchill","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0180","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.113.01337","article-title":"Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology","volume":"62","author":"Qi","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0185","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/ar3052","article-title":"Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation","volume":"12","author":"Chappell","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257016","article-title":"Development of ACE2 autoantibodies after SARS-CoV-2 infection","volume":"16","author":"Arthur","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/08916934.2021.1916915","article-title":"The prevalence and role of functional autoantibodies to angiotensin-converting-enzyme-2 in patients with systemic sclerosis","volume":"54","author":"Miziolek","year":"2021","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0200","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.158362","article-title":"IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function","volume":"7","author":"Casciola-Rosen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0205","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s10787-022-01008-9","article-title":"Plasma angiotensin peptides as biomarkers of rheumatoid arthritis are correlated with anti-ACE2 auto-antibodies level and disease intensity","volume":"30","author":"Khajeh Pour","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41531-022-00340-9","article-title":"Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson s disease","volume":"8","author":"Labandeira","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0215","article-title":"Angiotensin system autoantibodies correlate with routine prognostic indicators for COVID-19 severity","volume":"9","author":"Labandeira","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28273","article-title":"IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients","volume":"95","author":"Hallmann","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0225","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/HYPERTENSIONAHA.113.02856","article-title":"Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro","volume":"63","author":"Haber","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio806","article-title":"A clinical drug library screen identifies astemizole as an antimalarial agent","volume":"2","author":"Chong","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4162\/nrp.2007.1.1.29","article-title":"Cellular Zn depletion by metal ion chelators (TPEN, DTPA and chelex resin) and its application to osteoblastic MC3T3-E1 cells","volume":"1","author":"Cho","year":"2007","journal-title":"Nutr. Res. Pract."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0240","first-page":"L17","article-title":"Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin\/BKB1R axis and facilitates LPS-induced neutrophil infiltration","volume":"314","author":"Sodhi","year":"2018","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0245","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1039\/C7CS00521K","article-title":"Self-assembling prodrugs","volume":"46","author":"Cheetham","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0250","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1021\/ja3115983","article-title":"Supramolecular nanostructures formed by anticancer drug assembly","volume":"135","author":"Cheetham","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0255","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jconrel.2020.01.003","article-title":"Self-assembling and self-formulating prodrug hydrogelator extends survival in a glioblastoma resection and recurrence model","volume":"319","author":"Schiapparelli","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0260","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1073\/pnas.1913655117","article-title":"The role of critical micellization concentration in efficacy and toxicity of supramolecular polymers","volume":"117","author":"Su","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0265","doi-asserted-by":"crossref","first-page":"17107","DOI":"10.1021\/jacs.9b09848","article-title":"Macrocyclization of a class of Camptothecin analogues into tubular supramolecular polymers","volume":"141","author":"Su","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0270","article-title":"Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0275","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.1021\/acsnano.0c03286","article-title":"Supramolecular Tubustecan hydrogel as chemotherapeutic carrier to improve tumor penetration and local treatment efficacy","volume":"14","author":"Wang","year":"2020","journal-title":"ACS Nano"},{"issue":"17","key":"10.1016\/j.jconrel.2023.10.025_bb0280","doi-asserted-by":"crossref","first-page":"10651","DOI":"10.1021\/acsnano.3c01748","article-title":"Supramolecular filament hydrogel as a universal immunomodulator carrier for immunotherapy combinations","volume":"11","author":"Wang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0285","first-page":"1090","article-title":"Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel, Nat","volume":"4","author":"Wang","year":"2020","journal-title":"Biomed. Eng."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0290","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/btm2.10096","article-title":"Harnessing nanostructured systems for improved treatment and prevention of HIV disease","volume":"3","author":"Monroe","year":"2018","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0295","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jconrel.2022.06.037","article-title":"Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections","volume":"348","author":"Monroe","year":"2022","journal-title":"J. Control. Release"},{"issue":"145","key":"10.1016\/j.jconrel.2023.10.025_bb0300","doi-asserted-by":"crossref","first-page":"21293","DOI":"10.1021\/jacs.3c05645","article-title":"Constructing antiretroviral supramolecular polymers as Long-acting Injectables through rational Design of Drug Amphiphiles with alternating antiretroviral-based and hydrophobic residues","volume":"39","author":"Wang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0305","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1039\/D2BM01649D","article-title":"Antiviral supramolecular polymeric hydrogels by self-assembly of tenofovir-bearing peptide amphiphiles","volume":"11","author":"Monroe","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0310","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1021\/acsnano.7b02325","article-title":"Sequence-dependent self-assembly and structural diversity of islet amyloid polypeptide-derived beta-sheet fibrils","volume":"11","author":"Wang","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bip.21328","article-title":"Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials","volume":"94","author":"Cui","year":"2010","journal-title":"Peptide Sci.: Orig. Res. Biomol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0320","doi-asserted-by":"crossref","first-page":"12461","DOI":"10.1021\/ja507051w","article-title":"Amino acid sequence in constitutionally isomeric tetrapeptide amphiphiles dictates architecture of one-dimensional nanostructures","volume":"136","author":"Cui","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0325","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1021\/jacs.6b11512","article-title":"Aromatic-aromatic interactions enable alpha-Helix to beta-sheet transition of peptides to form supramolecular hydrogels","volume":"139","author":"Li","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0330","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1586","article-title":"Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases","volume":"12","author":"Anderson","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0340","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2019.10.026","article-title":"Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide","volume":"314","author":"Qiu","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0345","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2023.03.037","article-title":"Rational design of a polysaccharide-based viral mimicry nanocomplex for potent gene silencing in inflammatory tissues","volume":"357","author":"Gao","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0350","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2022.10.006","article-title":"Interplay between mucus mobility and alveolar macrophage targeting of surface-modified liposomes","volume":"352","author":"Japiassu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0355","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2020.11.057","article-title":"Learning from past failures: challenges with monoclonal antibody therapies for COVID-19","volume":"329","author":"Lai","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jconrel.2021.08.024","article-title":"Exosome membrane-modified M2 macrophages targeted nanomedicine: treatment for allergic asthma","volume":"338","author":"Pei","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0365","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jconrel.2022.03.028","article-title":"Lung targeted liposomes for treating ARDS","volume":"346","author":"Raviv","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0370","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jconrel.2021.07.044","article-title":"Sialic acid-conjugate modified doxorubicin nanoplatform for treating neutrophil-related inflammation","volume":"337","author":"Wang","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0375","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jconrel.2020.02.030","article-title":"Inflammation-targeting polymeric nanoparticles deliver sparfloxacin and tacrolimus for combating acute lung sepsis","volume":"321","author":"Yang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2023.06.018","article-title":"Delivery systems of therapeutic nucleic acids for the treatment of acute lung injury\/acute respiratory distress syndrome","volume":"360","author":"Zhuang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.025_bb0385","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm0303812","article-title":"Lessons learned from marketed and investigational prodrugs","volume":"47","author":"Ettmayer","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0390","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.tips.2022.03.003","article-title":"Supramolecular nanomedicines through rational design of self-assembling prodrugs","volume":"43","author":"Wang","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2023.10.025_bb0395","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.addr.2016.06.015","article-title":"Peptide\u2013drug conjugates as effective prodrug strategies for targeted delivery","volume":"110","author":"Wang","year":"2017","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923006752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923006752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:08:18Z","timestamp":1778674098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923006752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":79,"alternative-id":["S0168365923006752"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.025","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}